Publication: Unesbulin: A novel anti-tubulin cancer therapeutic

This research article, published in the Journal of Clinical Haematologyreports on the pharmacokinetic properties of unesbulin (PTC596), including safety and tolerability data, based on results of a Phase I, first-in-human study 

  • Unesbulin is a novel molecule being investigated for the treatment of cancer because of its ability to reduce levels of the BMI1 protein, which prevents the survival of cancer stem cells
  • An overview of the mechanism of action of unesbulin and a comparison with properties of other anti-tubulin agents are presented
  • Results from a Phase I dose-escalation study of unesbulin in 31 patients with advanced solid tumors are discussed

Gao L, Weetall M, O’Keefe K, et al. J Clin Haematol. 2021;2(3):80–85 

Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

  • PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at:

You can unsubscribe from updates at any time when receiving an email from PTC.

MED-ALL-DIPG-2100031 | March 2023
Sign in or register to access exclusive content on this site 

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
MED-ALL-CORP-2200029 | December 2022


The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.